Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07463846) titled 'A Study to Evaluate ALN-2232 in Participants With Obesity' on March 6.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
Primary Sponsor: Alnylam Pharmaceuticals
Condition:
Obesity
Intervention:
Drug: ALN-2232
Drug: Placebo
Recruitment Status: Recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: March 2, 2026
Target Sample Size: 156
Countries of Recruitment:
Canada
To know more, visit https://clinicaltrials.gov/study/NCT07463846
Published by HT Digita...